title: Monotherapy with docetaxel in second- or third-line treatment of anthracycline-resistant metastatic breast cancer.
abstract: Nineteen breast cancer patients pretreated with one or two anthracycline-containing regimens for visceral metastases received i.v. docetaxel 100 mg/m2 on day 1, q 21d. Docetaxel was administered as second-line therapy in 11 patients, whereas eight patients received docetaxel in a third-line setting. In the second-line setting, complete response (CR) was achieved in two (18%), partial response (PR) in four (36%) and stable disease (SD) in three (27%) patients resulting in a response rate (RR) of 54%. In the third-line setting three (38%) patients experienced PR (RR 38%) and two (25%) SD. In the second-line setting, median time to progression was 6.5+/-3.9 months (range 2.1-15.8) versus 4.7+/-5.5 months (range 0.6-15.9) in the third-line setting. Median overall survival was 9.6+/-8.0 months (range 2.7-25.8) versus 11.2-6.1 months (range 4.8-18.7). Overall, no patient experienced treatment-limiting toxicities. We conclude that docetaxel induced responses in 48% of anthracycline-resistant patients enrolled into the present study. The safety profile of docetaxel was manageable and tolerable. Docetaxel represented efficacious treatment in patients with metastatic breast cancer progressing despite previous anthracycline-containing chemotherapy.
authors.affiliation: Department of Medicine I, University Hospital, Vienna, Austria.
authors.forename: T
authors.initials: T
authors.lastname: Brodowicz
authors.forename: W J
authors.initials: WJ
authors.lastname: Koestler
authors.forename: S
authors.initials: S
authors.lastname: Tomek
authors.forename: I
authors.initials: I
authors.lastname: Vaclavik
authors.forename: V
authors.initials: V
authors.lastname: Herscovici
authors.forename: C
authors.initials: C
authors.lastname: Wiltschke
authors.forename: G G
authors.initials: GG
authors.lastname: Steger
authors.forename: C C
authors.initials: CC
authors.lastname: Zielinski
mesh_terms: D000328:Adult; D018943:Anthracyclines; D000972:Antineoplastic Agents, Phytogenic / Q000008:administration & dosage / Q000627:therapeutic use*; D001317:Austria / Q000453:epidemiology; D001943:Breast Neoplasms / Q000188:drug therapy* / Q000401:mortality / Q000473:pathology*; D000077143:Docetaxel; D019008:Drug Resistance, Neoplasm; D005260:Female; D006801:Humans; D007262:Infusions, Intravenous; D008875:Middle Aged; D009362:Neoplasm Metastasis; D017239:Paclitaxel / Q000008:administration & dosage / Q000031:analogs & derivatives* / Q000627:therapeutic use; D016879:Salvage Therapy; D016019:Survival Analysis; D043823:Taxoids; D016896:Treatment Outcome
chemical_list: D018943:Anthracyclines; D000972:Antineoplastic Agents, Phytogenic; D043823:Taxoids; D000077143:Docetaxel; D017239:Paclitaxel